The relevance of dopaminergic level in nocturnal disability in Parkinson's disease: Implications of continuous dopaminergic stimulation at night to treat the symptoms

Journal of Neural Transmission

Volumn 121, Issue SUPPL. 1, 2014, Pages

  Stocchi, Fabrizio ^a   Stirpe, Paola ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Apomorphine; CDS; Dopamine agonist; Levodopa; Parkinson's disease; Sleep

Indexed keywords

ANTIPARKINSON AGENT; DOPAMINE RECEPTOR STIMULATING AGENT;

HUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SLEEP DISORDERS;

ANTIPARKINSON AGENTS; DOPAMINE AGENTS; HUMANS; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SLEEP DISORDERS;

EID: 84905090380     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-014-1259-2     Document Type: Review

References (45)

1. Baas HK, Schueler P (2001) Efficacy of cabergoline in long-term use: results of three observational studies in 1500 patients with Parkinson's disease. Eur Neurol 46(Suppl 1):18-23 (Pubitemid 34008779)
2. Barone P, Amboni M, Vitale C, Bonavita V (2004) Treatment of nocturnal disturbances and excessive daytime sleepiness in Parkinson's disease. Neurology 63(8 Suppl 3):S35-S38 (Pubitemid 39426259)
3. Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP et al (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 24:1641-1649
4. Chaudhuri KR, Clough C (1998) Subcutaneous apomorphine in Parkinson's disease. BMJ 316(7132):641 (Pubitemid 28121017)
5. Chaudhuri KR, Logishetty K (2009) Dopamine receptor agonists and sleep disturbances in Parkinson's disease. Parkinsonism Relat Disord 15(Suppl 4):S101-S104
6. Christmas TJ, Kempster PA, Chapple CR, Frankel JP, Lees AJ, Stern GM, Milroy EJ (1988) Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 2(8626-8627):1451-1453 (Pubitemid 19016651)
7. Factor SA, Weiner WJ (1998) Sleep benefit in Parkinson's disease. Neurology 50(5):1514-1515
8. Factor S, McAlarney T, Sanchez-Ramos JR, Weiner WJ (1990) Sleep disorders and sleep effect in Parkinson's disease. Mov Disord 5:280-285 (Pubitemid 20373607)
9. Fernandez HH, Odin P (2011) Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease. Curr Med Res Opin 27(5):907-919
10. Friedman A (1980) Sleep pattern in Parkinson's disease. Acta Med Pol 21(2):193-199
11. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S (1999) Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 10(52(9)):1908-1910
12. Garcia Ruiz PJ (2006) Nocturnal subcutaneous apomorphine infusion for severe insomnia in Parkinson's disease. Mov Disord 21(5):727-728
13. Ghys L, Surmann E, Whitesides J, Boroojerdi B (2011) Effect of rotigotine on sleep and quality of life in Parkinson's disease patients: post hoc analysis of RECOVER patients who were symptomatic at baseline. Expert Opin Pharmacother 12(13):1985-1998
14. Giladi N, Fichtner A, Poewe W, Boroojerdi B (2010) Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson's disease. J Neural Transm 117(12):1395-1399
15. Högl B, Rothdach A, Wetter TC, Trenkwalder C (2003) The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson's disease. Neuropsychopharmacology 28(10):1866-1870 (Pubitemid 41070852)
16. Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, Fox K, Mancini F, Canesi M, Odin P, Chaudhuri KR (2009) Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 24(10):1468-1474
17. Jansen EN, Meerwaldtt JD (1990) Madopar HBS in nocturnal symptoms of Parkinson's disease. Adv Neurol 53:527-531
18. Jellinger KA (1991) Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 14(3):153-197
19. Johns MV (1993) Daytime sleepiness, snoring and obstructive sleep apnea. The Epworth Sleepiness Scale. Chest 103:30-36
20. Kales AN, Phang JM (1971) The effect of divided calcium intake on calcium metabolism. J Clin Endocrinol Metab 32(1):83-87
21. Kelly DD (1991) Disorders of sleep and consciousness. In: Kandel ER, Schwartz JH, Jessel TM (eds) Principles of neuronal science. Appleton and Lange, Norwalk, pp 805-819
22. Leeman AL, O'Neill CJ, Nicholson PW, Deshmukh AA, Denham MJ, Royston JP, Dobbs RJ, Dobbs SM (1987) Parkinson's disease in the elderly: response to an optimal spacing of night time dosing with levodopa. Br J Clin Pharmacol 24(5):637-643 (Pubitemid 18078359)
23. Lees AJ, Blackburn NA, Campbell VL (1988) The nighttime problems of Parkinson's disease. Clin Neuropharm 11:512-519 (Pubitemid 19006460)
24. Martinez-Martin P, Jeukens-Visser M, Lyons KE, Rodriguez-Blazquez C, Selai C, Siderowf A, Welsh M, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG, Schrag A (2011) Health-related quality-of-life scales in Parkinson's disease: critique and recommendations. Mov Disord 26(13):2371-2380
25. Pahwa R, Busenbark K, Huber SJ, Michalek D, Hubble JP, Koller WC (1993) Clinical experience with controlled-release carbidopa/levodopa in Parkinson's disease. Neurology 43(4):677-681 (Pubitemid 23121955)
26. Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, Elmer LW, Truong DD, Earl NL, EASE-PD Adjunct Study Investigators (2007) Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 68(14):1108-1115 (Pubitemid 46559844)
27. Pastor P, Tolosa E (2003) Cabergoline in the treatment of Parkinson's disease. Neurologia 18(4):202-209 (Pubitemid 36934747)
28. Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B, SP 515 Investigators (2007) Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 6(6):513-520 (Pubitemid 46734759)
29. Priano L, Albani G, Brioschi A, Guastamacchia G, Calderoni S, Lopiano L, Rizzone M, Cavalli R, Gasco MR, Fraschini F, Bergamasco B, Mauro A (2003) Nocturnal anomalous movement reduction and sleep microstructure analysis in parkinsonian patients during 1-night transdermal apomorphine treatment. Neurol Sci 24(3):207-208 (Pubitemid 37304316)
30. Ray Chaudhuri K, Martinez-Martin P, Rolfe KA, Cooper J, Rockett CB, Giorgi L, Ondo WG (2012) Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson's disease. Eur J Neurol 19:105-113
31. Reichmann H, Cooper J, Rolfe K, Martinez-Martin P (2011) Sleep duration and "on' time during different periods of the day and night in patients with advanced Parkinson's disease receiving adjunctive ropinirole prolonged release. Parkinsons Dis 2011:354760
32. Reuter I, Ellis CM, Ray Chaudhuri K (1999) Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neurol Scand 100(3):163-167 (Pubitemid 29376827)
33. Rinne UK, Larsen JP, Siden A, Worm-Petersen J (1998) Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 51(5):1309-1314 (Pubitemid 28520549)
34. Sanford M, Scott LJ (2011) Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease. CNS Drugs 25(8):699-719
35. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C (2011) The movement disorder society evidence-based medicine review update: treatments for the nonmotor symptoms of Parkinson's disease. Mov Disord 26(Suppl 3):S42-S80
36. Stocchi F, Destée A (1998) Co-administration of ropinirole and domperidone during rapid dose escalation of the dopamine agonist. Parkinsonism Relat Disord 4(4):183-188 (Pubitemid 29183255)
37. Stocchi F, Ruggieri S, Baronti F, Bellantuono P, Brughita G, Antonini A, Bravi D, Agnoli A (1987) On-off phenomena in Parkinson's disease. Continuous dopaminergic stimulation. Clin Ter 122(2):83-88 (Pubitemid 17132576)
38. Stocchi F et al (2000) Sleep disturbances in Parkinson's disease. Eur J Neurol 7(Suppl. 4):21-25
39. Stocchi F, Vacca L, Valente M, Ruggieri S (2001) Sleep disorders in Parkinson's disease. Adv Neurol 86:289-293
40. Tandberg E, Larsen JP, Karlsen K (1999) Excessive daytime sleepiness and sleep benefit in Parkinson's disease: a community-based study. Mov Disord 14:922-927
41. Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P, Hill D, Anderson T, Myllyla V, Kassubek J, Steiger M, Zucconi M, Tolosa E, Poewe W, Surmann E, Whitesides J, Boroojerdi B, Chaudhuri KR, Recover Study Group (2011) Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 26(1):90-99
42. Tribl GG, Sycha T, Kotzailias N, Zeitlhofer J, Auff E (2005) Apomorphine in idiopathic restless legs syndrome: an exploratory study. J Neurol Neurosurg Psychiatry 76(2):181-185 (Pubitemid 40143704)
43. Van den Kerchove M, Jacquy J, Gonce M, De Deyn PP (1993) Sustained-release levodopa in parkinsonian patients with nocturnal disabilities. Acta Neurol Belg 93(1):32-39 (Pubitemid 23089926)
44. Wailke S, Herzog J, Witt K, Deuschl G, Volkmann J (2011) Effect of controlled-release levodopa on the microstructure of sleep in Parkinson's disease. Eur J Neurol 18(4):590-596
45. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356(1):39-46 (Pubitemid 46041752)